Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) reported significant updates during the recent ASH meeting, showcasing initial data from its ALLO-715 AlloCAR T therapy for relapsed/refractory multiple myeloma. The Phase 1 UNIVERSAL trial demonstrated a 60% overall response rate with 40% achieving a very good partial response. The company ended 2020 with $1 billion in cash and plans to submit multiple IND applications in 2021. Financial guidance predicts operating expenses between $300 million and $330 million, reflecting continued investment in innovative CAR T therapies.
Allogene Therapeutics (Nasdaq: ALLO) plans to report its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A live audio webcast and conference call will follow at 2:00 PM PT/5:00 PM ET. Investors can access the webcast on the company's website. Allogene focuses on developing allogeneic CAR T therapies to provide more accessible cancer treatments. The press release emphasizes the company's commitment to delivering 'off-the-shelf' therapies at scale.
Allogene Therapeutics (Nasdaq: ALLO) announced plans to participate in four virtual investor conferences in February and March 2021. Key events include the Guggenheim Healthcare Talks on February 11, the Cowen 41st Annual Health Care Conference on March 3, the 33rd Annual Roth Conference on March 15, and Oppenheimer's 31st Annual Healthcare Conference on March 16. These events will showcase Allogene's progress in developing allogeneic CAR T therapies for cancer. Webcast details and replays will be available on the company's website.
Allogene Therapeutics (Nasdaq: ALLO) announced that Dr. Ton Schumacher has received the 2021 Jeantet-Collen Prize for Translational Medicine. This award acknowledges his advancements in cancer immunotherapy and the understanding of immune responses to cancer cells. Schumacher's work is expected to enhance cancer diagnosis and treatment. As a leading researcher and chair of Allogene’s Scientific Advisory Board, his leadership is vital as the company develops innovative AlloCAR T™ therapies. The award includes funding for his ongoing research into tumor antigens and immune microenvironments.
Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. Pacific Time. David Chang, M.D., Ph.D., the company's President and CEO, will lead the presentation. A live webcast will be available on Allogene's website with a replay accessible for 30 days. The company focuses on developing allogeneic CAR T therapies, aiming to provide readily available cancer treatments at scale.
Allogene Therapeutics (Nasdaq: ALLO) has announced that the FDA has approved its IND application to study ALLO-715 in combination with nirogacestat for multiple myeloma patients. This Phase 1 clinical trial, part of Allogene's strategy to target BCMA, is expected to begin enrollment in Q1 2021. The combination aims to enhance the effectiveness of ALLO-715 by preventing BCMA cleavage, potentially leading to improved patient responses. The collaboration with SpringWorks Therapeutics is pivotal for this study, with Allogene assuming development costs.
Allogene Therapeutics and Overland Pharmaceuticals have formed a joint venture called Allogene Overland Biopharm to develop AlloCAR T™ therapies for hematologic malignancies and solid tumors in Greater China, Taiwan, South Korea, and Singapore. Overland will invest $117 million, including a $40 million upfront payment. The venture aims to accelerate the availability of these therapies in Asia, with Allogene providing technical expertise and Overland offering operational support. Allogene retains global rights for their investigational candidates and will receive milestone payments upon regulatory approvals.
Allogene Therapeutics (Nasdaq: ALLO) announced significant preclinical findings for its investigational drug ALLO-605, a next-generation CAR T therapy targeting multiple myeloma. The results indicate that ALLO-605 exhibited enhanced killing of myeloma cells and greater persistence compared to traditional BCMA CAR T therapies. The company plans to file an Investigational New Drug (IND) application for ALLO-605 in the first half of 2021. TurboCAR technology, used in ALLO-605, aims to improve the efficacy of CAR T therapies by enhancing T cell activity and proliferation.
Allogene Therapeutics has announced promising preclinical results for ALLO-316, an AlloCAR T™ therapy targeting CD70, effective against leukemic cells in acute myeloid leukemia (AML). The U.S. FDA has cleared an Investigational New Drug (IND) application for ALLO-316, with a Phase 1 trial in renal cell carcinoma (RCC) set to start in 2021. These findings suggest ALLO-316's potential in treating both hematologic malignancies and solid tumors, reinforcing the importance of CD70 as a target across various cancers.
Allogene Therapeutics has announced promising data from the Phase 1 UNIVERSAL study of ALLO-715 for relapsed/refractory multiple myeloma. As of October 30, 2020, the study involved 35 patients, with 31 evaluable for safety and 26 for efficacy. The study reported a 60% overall response rate and a 40% very good partial response rate, with no instances of graft-versus-host disease or severe neurotoxicity observed. The data highlight the potential of ALLO-715 as an effective off-the-shelf therapy with fast treatment initiation, supporting its continued development and trials in the future.